1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [01839bae-7a1c-4508-91b3-c1242569ddf8] => Array
        (
            [runtime-id] => 01839bae-7a1c-4508-91b3-c1242569ddf8
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [0ce17c96-f966-427c-9e15-631b9be3b255] => Array
                        (
                            [runtime-id] => 0ce17c96-f966-427c-9e15-631b9be3b255
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;33f6e05c02a40d8c90154d40549ca4e226f4cc1b
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [cb8b71a0-efe1-4889-8e86-ab7ee2e8153e] => Array
        (
            [runtime-id] => cb8b71a0-efe1-4889-8e86-ab7ee2e8153e
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [b9ac1df4-df63-48b2-9f6d-2e2c065c9e72] => Array
                        (
                            [runtime-id] => b9ac1df4-df63-48b2-9f6d-2e2c065c9e72
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;33f6e05c02a40d8c90154d40549ca4e226f4cc1b
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [cb8b71a0-efe1-4889-8e86-ab7ee2e8153e] => Array
        (
            [runtime-id] => cb8b71a0-efe1-4889-8e86-ab7ee2e8153e
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [b9ac1df4-df63-48b2-9f6d-2e2c065c9e72] => Array
                        (
                            [runtime-id] => b9ac1df4-df63-48b2-9f6d-2e2c065c9e72
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;33f6e05c02a40d8c90154d40549ca4e226f4cc1b
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [cb8b71a0-efe1-4889-8e86-ab7ee2e8153e] => Array
        (
            [runtime-id] => cb8b71a0-efe1-4889-8e86-ab7ee2e8153e
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [b9ac1df4-df63-48b2-9f6d-2e2c065c9e72] => Array
                        (
                            [runtime-id] => b9ac1df4-df63-48b2-9f6d-2e2c065c9e72
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;33f6e05c02a40d8c90154d40549ca4e226f4cc1b
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [cb8b71a0-efe1-4889-8e86-ab7ee2e8153e] => Array
        (
            [runtime-id] => cb8b71a0-efe1-4889-8e86-ab7ee2e8153e
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [b9ac1df4-df63-48b2-9f6d-2e2c065c9e72] => Array
                        (
                            [runtime-id] => b9ac1df4-df63-48b2-9f6d-2e2c065c9e72
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;33f6e05c02a40d8c90154d40549ca4e226f4cc1b
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [cb8b71a0-efe1-4889-8e86-ab7ee2e8153e] => Array
        (
            [runtime-id] => cb8b71a0-efe1-4889-8e86-ab7ee2e8153e
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [b9ac1df4-df63-48b2-9f6d-2e2c065c9e72] => Array
                        (
                            [runtime-id] => b9ac1df4-df63-48b2-9f6d-2e2c065c9e72
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;33f6e05c02a40d8c90154d40549ca4e226f4cc1b
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [8d0e4f0d-f0be-4e7f-8073-8c121b5b4f3c] => Array
        (
            [runtime-id] => 8d0e4f0d-f0be-4e7f-8073-8c121b5b4f3c
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [2384d83c-dd12-4fbc-8774-0117d04c1bb8] => Array
                        (
                            [runtime-id] => 2384d83c-dd12-4fbc-8774-0117d04c1bb8
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;33f6e05c02a40d8c90154d40549ca4e226f4cc1b
                )

        )

)


  
    











    Incidence and Risk Factors of In-Stent Restenosis for Symptomatic Intracranial Atherosclerotic Stenosis: A Systematic Review and Meta-Analysis | American Journal of Neuroradiology  
    


















    


























    
  
  




    
    

  

      


    

      

  
  
  

    

  

    

  

                
    

      

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



    

  


  


  


  
  
  
  
  
  

  	      


    
      

    
  
    
        
    

  

    
                        

  

                
    

      

  

    

  
      
  
  

    

  
  
      
Research ArticleInterventional

  
      

  
      
Incidence and Risk Factors of In-Stent Restenosis for Symptomatic Intracranial Atherosclerotic Stenosis: A Systematic Review and Meta-Analysis
  
    	
G. Peng, Y. Zhang and Z. Miao

  
    	
American Journal of Neuroradiology August 2020,  41 (8) 1447-1452; DOI: https://doi.org/10.3174/ajnr.A6689 

  
  
  



  


  
  



  
      
  
  

    
Abstract
BACKGROUND: In-stent restenosis affects long-term outcome in patients with intracranial atherosclerotic stenosis.
PURPOSE: The aim of this meta-analysis was to evaluate the incidence and risk factors of in-stent restenosis.
DATA SOURCES: All literature that reported in-stent restenosis was searched on PubMed, Ovid EMBASE and Ovid MEDLINE data bases.
STUDY SELECTION: Original articles about stents for symptomatic intracranial atherosclerotic stenosis were selected.
DATA ANALYSIS: Meta-analysis was conducted to derive the pooled in-stent restenosis using a random-effects model. Meta-regression was performed to explore the risk factors predisposing to in-stent restenosis.
DATA SYNTHESIS: In total, 51 studies with 5043 patients were included. The pooled incidence rate of in-stent restenosis was 14.8% (95% CI, 11.9%–17.9%). Among the lesions with in-stent restenosis, 28.8% of them led to (95% CI, 22.0%–36.0%) related neurologic symptoms. The series in the United States had a higher in-stent restenosis rate (27.0%; 95% CI, 20.6%–33.9%) compared with those from Asia (13.6%; 95% CI, 10.3%–17.2%) and other regions as a whole (7.6%; 95% CI, 1.1%–18.1%) (P < .01). Multiregression analysis revealed that younger patient age was related to high in-stent restenosis rates (P = .019), and vertebrobasilar junction location (P = .010) and low residual stenosis (P = .018) were 2 independent risk factors for symptomatic in-stent restenosis rate.
LIMITATIONS: The heterogeneity of most outcomes was high.
CONCLUSIONS: Our study showed promising results of in-stent restenosis for symptomatic atherosclerotic stenosis. Studies are needed to further expatiate on the mechanisms by which younger patient age, vertebrobasilar junction location, and low residual stenosis could increase in-stent restenosis and symptomatic in-stent restenosis, respectively.
ABBREVIATIONS:
ISR
in-stent restenosis
MINORS
Methodological Index for Non-Randomized Studies
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
SAMMPRIS
Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
SES
self-expandable stent
Intracranial atherosclerotic stenosis leads to a remarkable decrease of cerebral perfusion and is responsible for approximately 8%–10% of all ischemic strokes.1,2 According to the results of several randomized clinical trials, including the Warfarin-Aspirin Symptomatic Intracranial Disease Study (WASID), Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS), and VISSIT Intracranial Stent Study for Ischemic Therapy (VISSIT), the annual rate of recurrent strokes of patients with intracranial atherosclerotic stenosis could be as high as 12.2%–20.4% despite aggressive medical treatment.3-5 Stent placement as a major technique of endovascular treatment can reduce the stroke recurrence in patients who were refractory to aggressive medical treatment. The Wingspan Stent System Post Market Surveillance Study (WEAVE) has shown that the incidence of perioperative complications can be reduced to 2.6%.6 In-stent restenosis (ISR) is another important risk factor for long-term stroke recurrence in the patients with stents. Patients with ISR had an approximately 10% higher risk of an ischemic event, which occurred earlier simultaneously than those without ISR after stent implantation.7,8 The incidence of ISR differs among the available studies, varying from 5% to 30%, and reliable analyses of risk factors of ISR are still lacking until now.8-11 In this meta-analysis, we aimed to evaluate the incidence of ISR and identify the relative risk factors.
MATERIALS AND METHODS
Literature Search
We searched the literature (last search August 30, 2019) via the databases PubMed, Ovid EMBASE, and Ovid MEDLINE and following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.12 The inclusion criteria were stents for symptomatic intracranial atherosclerotic stenosis. The following key words were used and limited to the title and abstract: (“stent” or “stents” or “angioplasty”) and (“stenosis” or “atherosclerosis” or “atherosclerotic” or “occlusion”) and (“cerebral” or “intracranial”). The studies included had data of ISR as one of the outcomes. Exclusion criteria were the following: 1) articles written in languages other than English; 2) reviews, comments, protocols, editorials, letters, case reports, or animal trials; 3) studies with multiple treatments like primary balloon angioplasty or with extracranial artery stenosis in which data could not be separated; 4) studies on the treatment of complex cerebral artery stenosis; 5) studies on imaging evaluation or treatment of ISR; and 6) series with sample sizes of <20.
Data Extraction and Quality Scoring
We extracted the following data: 1) patient characteristics, including age, sex, hypertension, diabetes, hyperlipemia, smoking, coronary heart disease, ischemic stroke or TIA as a qualifying event, and duration from symptom to treatment; 2) lesion characteristics, including lesion location (internal carotid artery, middle cerebral artery, anterior cerebral artery, vertebral artery, basilar artery, vertebrobasilar artery, and posterior cerebral artery), degree of preprocedural stenosis, length and Mori type of lesion; 3) procedure-related characteristics, including stent type, procedural success, degree of residual stenosis, and periprocedural complications; and 4) image follow-up characteristics, including image follow-up rate, mean image follow-up time, ISR rate, and symptomatic ISR rate. ISR was defined as an angiographically verified >50% stenosis within or at the edge of the stent. All the included cohort studies were assessed by the Newcastle-Ottawa Scale and single-arm studies assessed by the Methodological Index for Non-Randomized Studies (MINORS) (On-line Tables 1 and 2).13,14 Studies with a Newcastle Ottawa Scale score of >5 and a MINORS score of >10 were considered high-quality studies.
View this table:
Analysis of meta-regression with in-stent restenosis according to patient population and characteristics
Statistical Analysis
Statistical heterogeneity of the data was measured by the Higgins index (I2), and the DerSimonian and Laird random-effects model was used. I2 < 60% was considered as little-to-moderate heterogeneity, while I2 > 60% was considered substantial heterogeneity. The pooled ISR was represented on a forest plot with 95% CI. The publication bias was assessed by the Egger test and was illustrated on a funnel plot (On-line Figs 1 and 2). All P values were 2-sided, and a statistically significant difference was P < .05. All analyses were performed with the “meta” and “metafor” packages in R statistical and computing software, Version 3.4.3 (http://www.r-project.org/).
RESULTS
Description of Studies
There were 646 studies found in the first search. After screening the article and assessing the full text, a total of 51 studies met the inclusion and exclusion criteria, and 5043 patients with 5168 lesions were included in our analysis.4,7⇓⇓⇓-11,15-59 Among these, 4 studies were prospective multicentric, 7 were single-center prospective, 8 were retrospective multicentric, and 32 were retrospective single-center series. The PRISMA flow diagram of our analysis is shown in On-line Fig 3.
Patient Population and Characteristics
The mean age of patients was 60.1 years (range, 48.1–70.5 years), and the proportion of male patients was 73.6% (3712/5043; 95% CI, 71.1%–76.1%; I2 = 71%). The most common risk factors were hypertension (3772/5043 = 74.8%; 95% CI, 70.9%–78.7%; I2 = 87%), hyperlipidemia (2416/5043  =  47.9%; 95% CI, 42.1%–54.6%; I2 = 95%), smoking (2073/5043  =  41.1%; 95% CI, 34.9%–47.3%; I2 = 93%), diabetes (1725/5043  =  34.2%; 95% CI, 30.0%–38.4%; I2 = 88%), and coronary artery disease (908/5043 = 18.0%; 95% CI, 15.0%–20.9%; I2 = 69%). As the qualifying agent, 57.2% of patients (2885/5043; 95% CI, 50.8%–63.6%; I2 = 94%) had ischemic stroke, while 41.2% patients (2078/5043; 95% CI, 34.2%–48.3; I2 = 94%) had transient ischemic attack as the qualifying event.
On the whole, 57.1% of lesions (95% CI, 44.9%–68.8%; I2 = 98.5%) had anterior circulation artery stenosis, while 43.8% (95% CI, 31.9%–56.0%; I2 = 98.5%) were posterior circulation lesions. According to Mori type, Mori A was 24.1% (95% CI, 17.6%–31.1%; I2 = 86.6%), Mori B was 55.1% (95% CI, 48.1%-62.0%; I2 = 74.7%), and Mori C was 21.5% (95% CI, 14.7%–29.2%; I2 = 84.1%). Among these patients, balloon-mounted stents were used in 31.7% (95% CI, 16.3%–49.3%; I2 = 99.3%) of patients, and self-expandable stents were used in 68.3% (95% CI, 50.7%–83.7%; I2 = 99.3%).
ISR and Its Risk Factors
A total of 3652 lesions (70.7%) had imaging follow-up. The mean image follow-up time was 17.8 months (range, 5.9–180.0 months). For lesions with at least 1 imaging follow-up, the rate of ISR amounted to 14.8% (95% CI, 11.9%–17.9%; I2 = 82%) (On-line Fig 4).
The ISR rate was lower in older patients (P = .009) (On-line Fig 5). Prospective studies had higher ISR rates than retrospective studies (20.9%; 95% CI, 16.0%–26.3%; I2 = 69% versus 13.2%; 95% CI, 10.0%–16.7%; I2 = 82%; P = .02) (On-line Fig 6). Series in United States had higher ISR rates (27.0%; 95% CI, 20.6%–33.9%; I2 = 30%) compared with those from Asia (13.6%; 95% CI, 10.3%–17.2%; I2 = 83%) and other regions as a whole (7.6%; 95% CI, 1.1%–18.1%; I2 = 80%; P < .01) (On-line Fig 7). Meanwhile, the ISR rate was significantly higher in studies with imaging follow-up rates below 60% than in the studies with image follow-up rates above 60% (21.6%; 95% CI, 16.1%–27.6%; I2 = 73% versus 12.2%; 95% CI, 9.1%–15.7%; I2 = 83%; P < .01) (On-line Fig 8). Overall, the ISR rate was not statistically related to hypertension, diabetes, lesion location, length of stenosis, procedural success rate, degree of residual stenosis, and other variables (Table). Results of multiregression analysis showed that younger age was the only independent risk factor that predicted high ISR rates (P = .019).
Risk Factors for Symptomatic ISR
Among the lesions with ISR at follow-up, 28.8% (95% CI, 22.0%–36.0%; I2= 44%) were symptomatic. Meanwhile, the symptomatic ISR rate was 4.3% (95% CI, 3.0%–5.7%; I2= 53%) in the total study population.
First, symptomatic ISR was correlated to the sample size of the series. Symptomatic ISR increased as the sample enlarged (P = .001) (On-line Fig 9). Second, according to the results of subgroup analysis, the studies in the United States had higher symptomatic ISR rates (8.7%; 95% CI, 5.0%–13.2%; I2 = 0%) than those in Asia (4.3%; 95% CI, 3.1%–5.6%; I2 = 30%) and other regions (0.0%; 95% CI, 0.0%–2.3%; I2 = 0%) (P < .01). Third, older individuals also had lower symptomatic ISR rates (P = .046) (On-line Fig 10). Fourth, the symptomatic ISR rate was also lower in studies with an imaging follow-up rate of >60% than in the studies with an image follow-up rate of <60% (3.4%; 95% CI, 2.1%–5.1%; I2 = 58% versus 6%; 95% CI, 4%–9%; I2 = 28%, P = .02). In multivariate regression analysis, vertebrobasilar junction location (P = .010) and low residual stenosis (P = .018) were independent risk factors for the symptomatic ISR rate (On-line Figs 11 and 12).
Heterogeneity
Moderate heterogeneity between effect estimates was observed for Mori B and Mori C lesions. Substantial heterogeneity between effect estimates was observed in the following variables: age, male sex, hypertension, diabetes, hyperlipemia, smoking, ischemic stroke or TIA as the qualifying event, duration from symptom to treatment, lesion location, peristenosis, length of stenosis, Mori A lesion, procedural success rate, stent type, and image follow-up rate (Table).
DISCUSSION
Our meta-analysis showed that 14.8% of symptomatic patients with intracranial atherosclerotic stenosis after stent implantations may experience ISR. Among these patients with ISR, 28.8% would have symptoms. The symptomatic ISR rate was 4.3% in the whole patient population, which was much lower than that in the SAMMPRIS trial.60
The SAMMPRIS trial is a prospective randomized controlled trial whose subgroup analysis of symptomatic ISR included 183 patients, and the image follow-up rate was <60%. The result of our meta-analysis showed that prospective studies had higher ISR rates than retrospective studies due to younger age (58.8 ± 5.2 versus 60.4 ± 4.8 years, P = .37) in prospective studies, which was the risk factor for ISR. The symptomatic ISR rate was higher in the studies with relatively low image follow-up rates as well. Meanwhile, the subgroup analysis of SAMMPRIS of symptomatic ISR enrolled 4 patients with primary balloon angioplasty; therefore, this meta-analysis excluded it.
In our study, we found that the reported ISR rate decreased as the image follow-up rate increased because the low image follow-up rate reflected the overall patient compliance with physicians’ suggestions. The patients would not consider an invasive DSA follow-up until there were new-onset postprocedural symptoms. Therefore, in the series with a lower image follow-up rate, most of the patients came back only when they were symptomatic due to ISR. On the contrary, a higher image follow-up rate can reduce follow-up bias, and the ISR rate would be much closer to the real situation. Our study showed that when the rate of image follow-up was higher than 60%, the incidence of ISR and symptomatic ISR was significantly lower. The total image follow-up rate of this meta-analysis was 77.3%; among these studies, 35 studies (68.6%) had image follow-up rates above 60%, with ISR rates of 12.2% and symptomatic ISR rates of 3.4%. This finding might have certain guiding significance for further study designs.
Lesion location as one of risk factors of ISR has been described previously. In the series of Turk et al,58 the supraclinoid segment of the ICA tended to have higher ISR. In our study, the incidence of ISR and symptomatic ISR showed no notable difference between the anterior and posterior circulation, but a higher rate of symptomatic ISR was noticed in the lesions at the vertebrobasilar junction. Parent vessel tortuosity is more commonly seen in this location, thus hampering the apposition of the stent to the vessel wall and predisposing this location to higher risk of ISR.
Moreover, we also identified a disparity of reported ISR rates among different regions. Higher incidences of ISR and symptomatic ISR were observed in patients in the United States compared with patients in Asia and other areas like Germany, Italy, Turkey, and Argentina. There was no significant difference in procedural success rates and residual stenosis rates among different regions. The mean image follow-up rate of studies in the United States was 65.2%, lower than that of studies in other regions (79.7%) (P = .08). The studies in the United States also had lower residual stenosis rates (14.8% ± 5.2% versus 16.7% ± 8.2%, P = .654) and a higher proportion of vertebrobasilar junction locations (2.8% ± 4.3% versus 2.0% ± 7.7%, P = .038) than in other regions. Although without a statistical difference, these might have caused higher rates of ISR and symptomatic ISR in the studies in the United States.
Several studies have demonstrated that larger residual stenosis may be a predictor of restenosis after stent placement, especially when residual stenosis is >30%.45,51,52 This finding is in accordance with our instincts, because larger residual stenosis might reflect lesions not being adequately treated. What if the lesions are adequately treated? Should we more aggressively minimize the residual stenosis to the best result possible? In our analysis, most of the included studies (36/38, 94.7%) had a residual stenosis of under 30%, indicating that most of the lesions were properly handled. However, the multivariate regression analysis suggested that lower residual stenosis was related to higher symptomatic ISR rates. This result is surprising, but it might hint that treating the lesions more aggressively added no more benefit. When residual stenosis is <30%, lower residual stenosis may indicate more vascular endothelial damage during the procedure; that could lead to a higher risk of symptomatic ISR.
We also identified another counterintuitive factor, namely younger age, that led to higher ISR rates post-stent implantation. Turk et al58 also reported that ISR is more common in younger patients after treatment with the Wingspan system. One reason the authors hypothesized was that lesions in younger patients represented more of inflammatory arteriopathy than primary atherosclerosis. Previous research has shown that inflammatory connective tissue disease is associated with cardiovascular risk and there was a negative interaction between connective tissue disease and age.61 We suspect that the inflammatory response may be more active in younger patients with atherosclerotic disease facing a greater risk of ISR, but more proof and evidence are needed.
Our study showed no association between the ISR rate and different stent types, including balloon-mounted stents and self-expandable stents (SESs). Previous studies and a systematic review suggested that lesions with SESs were more prone to ISR than those with balloon-mounted stents due to the higher residual stenosis degree, higher flexibility, and the lower radial force of SESs.36,62,63 Our study presented higher degrees of residual stenosis after SES implantation as well (P = .033). The negative correlation between residual stenosis and the ISR rate found in this study may conceal positive correlations of SES. Further studies are needed to identify whether the lesions with SES have higher restenosis rates and the physiopathologic mechanism.
Several limitations of our meta-analysis need to be discussed. First, most studies were retrospective, and the sample size in 72% of series was <100 patients. The target population of studies varied within the inclusion criteria, resulting in limited generalization of population characteristics such as distribution of lesion location, proportion of stent types used, and preprocedural stenosis degree. Second, the variables extracted from studies were limited because of the meta-analysis design. Age and residual stenosis are important risk factors for ISR. However, we could only analyze the relationship between mean age and mean residual stenosis of each study and ISR. The platelet inhibition ratio, indicators of inflammatory response, serum lipid levels, and blood glucose levels during the follow-up period that may lead to ISR were rarely mentioned in the studies. Third, the patients’ enrollment in these studies spanned 2 decades (1996–2018), during which time the technique of intracranial stent implantation and the standardization and compliance of medications have improved. These factors may also have an effect on ISR. In addition, there was considerable heterogeneity in the effect estimates of some risk factors we studied.
Our study has some implications for clinical practice. The risk factors discussed in the meta-analysis could help neurointerventionists develop more cautious operation and image follow-up plans when patients have a high risk for ISR.
CONCLUSIONS
Our study showed promising results of in-stent restenosis for symptomatic atherosclerotic stenosis. Studies are needed to further expatiate on the mechanisms by which younger patient age, vertebrobasilar junction location, and low residual stenosis could increase ISR and symptomatic ISR, respectively.
References
  1. 1.
    1. Sacco  RL, 
    2. Kargman  DE, 
    3. Gu  Q, et al
    . Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction: the Northern Manhattan Stroke Study. Stroke 1995;26:14–20 doi:10.1161/01.str.26.1.14 pmid:7839388
  2. 2.
    1. Wityk  RJ, 
    2. Lehman  D, 
    3. Klag  M, et al
    . Race and sex differences in the distribution of cerebral atherosclerosis. Stroke 1996;27:1974–80 doi:10.1161/01.str.27.11.1974 pmid:8898801
  3. 3.
    1. Chimowitz  MI, 
    2. Lynn  MJ, 
    3. Derdeyn  CP, et al
    ; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011;365:993–1003 doi:10.1056/NEJMoa1105335 pmid:21899409
  4. 4.
    1. Zaidat  OO, 
    2. Fitzsimmons  BF, 
    3. Woodward  BK, et al
    ; VISSIT Trial Investigators. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA 2015;313:1240–48 doi:10.1001/jama.2015.1693 pmid:25803346
  5. 5.
    1. Chimowitz  MI, 
    2. Lynn  MJ, 
    3. Howlett-Smith  H, et al
    ; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305–16 doi:10.1056/NEJMoa043033 pmid:15800226
  6. 6.
    1. Alexander  MJ, 
    2. Zauner  A, 
    3. Chaloupka  JC, et al
    ; WEAVE Trial Sites and Interventionalists. WEAVE trial: final results in 152 on-label patients. Stroke 2019;50:889–94 doi:10.1161/STROKEAHA.118.023996 pmid:31125298
  7. 7.
    1. Jin  M, 
    2. Fu  X, 
    3. Wei  Y, et al
    . Higher risk of recurrent ischemic events in patients with intracranial in-stent restenosis. Stroke 2013;44:2990–94 doi:10.1161/STROKEAHA.113.001824 pmid:23963335
  8. 8.
    1. Levy  EI, 
    2. Turk  AS, 
    3. Albuquerque  FC, et al
    . Wingspan in-stent restenosis and thrombosis: incidence, clinical presentation, and management. Neurosurgery 2007;61:644–50; discussion 50–51 doi:10.1227/01.NEU.0000290914.24976.83 pmid:17881980
  9. 9.
    1. Alurkar  A, 
    2. Karanam  LS, 
    3. Oak  S, et al
    . Role of balloon-expandable stents in intracranial atherosclerotic disease in a series of 182 patients. Stroke 2013;44:2000–03 doi:10.1161/STROKEAHA.113.001446 pmid:23696549
  10. 10.
    1. Li  J, 
    2. Zhao  ZW, 
    3. Gao  GD, et al
    . Wingspan stent for high-grade symptomatic vertebrobasilar artery atherosclerotic stenosis. Cardiovasc Intervent Radiol 2012;35:268–78 doi:10.1007/s00270-011-0163-5 pmid:21516376
  11. 11.
    1. Zhang  L, 
    2. Huang  Q, 
    3. Zhang  Y, et al
    . Wingspan stents for the treatment of symptomatic atherosclerotic stenosis in small intracranial vessels: safety and efficacy evaluation. AJNR Am J Neuroradiol 2012;33:343–47 doi:10.3174/ajnr.A2772 pmid:22173759
  12. 12.
    1. Moher  D, 
    2. Liberati  A, 
    3. Tetzlaff  J, et al
    ; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12 doi:10.1016/j.jclinepi.2009.06.005 pmid:19631508
  13. 13.
    1. Slim  K, 
    2. Nini  E, 
    3. Forestier  D, et al
    . Methodological Index for Non-Randomized Studies (MINORS): development and validation of a new instrument. ANZ J Surg 2003;73:712–76 doi:10.1046/j.1445-2197.2003.02748.x pmid:12956787
  14. 14.
    1. Wells  GA, 
    2. Shea  B, 
    3. O’Connell  D, et al
    . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonradomized studies in meta-analyses. 2014. Ottawal Hospital Research Institute. https://www.researchgate.net/publication/288802810_The_Newcastle-Ottawa_Scale_NOS_for_Assessing_The_Quality_of_Nonrandomised_Studies_in_Meta-analyses. Assessed November 19, 2019
  15. 15.
    1. Bai  WX, 
    2. Gao  BL, 
    3. Li  TX, et al
    . Wingspan stenting can effectively prevent long-term strokes for patients with severe symptomatic atherosclerotic basilar stenosis. Interv Neuroradiol 2016;22:318–24 doi:10.1177/1591019915623797 pmid:26823331
  16. 16.
    1. Bose  A, 
    2. Hartmann  M, 
    3. Henkes  H, et al
    . A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the Wingspan study. Stroke 2007;38:1531–57 doi:10.1161/STROKEAHA.106.477711 pmid:1739586
  17. 17.
    1. Du  Z, 
    2. Mang  J, 
    3. Yu  S, et al
    . Weighing in on the off-label use: initial experience of Neuroform EZ stenting for intracranial arterial stenosis in 45 patients. Front Neurol 2018;9:852 doi:10.3389/fneur.2018.00852 pmid:30364175
  18. 18.
    1. Durst  CR, 
    2. Geraghty  SR, 
    3. Southerland  AM, et al
    . Stenting of symptomatic intracranial stenosis using balloon mounted coronary stents: a single center experience. J Neurointerv Surg 2015;7:245–49 doi:10.1136/neurintsurg-2014-011185 pmid:24646693
  19. 19.
    1. Feng  Z, 
    2. Duan  G, 
    3. Zhang  P, et al
    . Enterprise stent for the treatment of symptomatic intracranial atherosclerotic stenosis: an initial experience of 44 patients. BMC Neurol 2015;15:187 doi:10.1186/s12883-015-0443-9 pmid:26449986
  20. 20.
    1. Fiorella  D, 
    2. Chow  MM, 
    3. Anderson  M, et al
    . A 7-year experience with balloon-mounted coronary stents for the treatment of symptomatic vertebrobasilar intracranial atheromatous disease. Neurosurgery 2007;61:236–42; discussion 42–43 doi:10.1227/01.NEU.0000255521.42579.31 pmid:17762735
  21. 21.
    1. Freitas  JM, 
    2. Zenteno  M, 
    3. Aburto-Murrieta  Y, et al
    . Intracranial arterial stenting for symptomatic stenoses: a Latin American experience. Surg Neurol 2007;68:378–86 doi:10.1016/j.surneu.2006.11.062 pmid:17905061
  22. 22.
    1. Gandini  R, 
    2. Chiaravalloti  A, 
    3. Pampana  E, et al
    . Intracranial atheromatous disease treatment with the Wingspan stent system: evaluation of clinical, procedural outcome and restenosis rate in a single-center series of 21 consecutive patients with acute and mid-term results. Clin Neurol Neurosurg 2013;115:741–47 doi:10.1016/j.clineuro.2012.08.037 pmid:22989778
  23. 23.
    1. Guo  XB, 
    2. Ma  N, 
    3. Hu  XB, et al
    . Wingspan stent for symptomatic M1 stenosis of middle cerebral artery. Eur J Radiol 2011;80:e356–60 doi:10.1016/j.ejrad.2010.11.029 pmid:21163599
  24. 24.
    1. He  Y, 
    2. Wang  Z, 
    3. Li  T, et al
    . Preliminary findings of recanalization and stenting for symptomatic vertebrobasilar artery occlusion lasting more than 24h: a retrospective analysis of 21 cases. Eur J Radiol 2013;82:1481–86 doi:10.1016/j.ejrad.2013.04.021 pmid:23706495
  25. 25.
    1. Jiang  WJ, 
    2. Cheng-Ching  E, 
    3. Abou-Chebl  A, et al
    . Multicenter analysis of stenting in symptomatic intracranial atherosclerosis. Neurosurgery 2012;70:25–30; discussion 31 doi:10.1227/NEU.0b013e31822d274d
  26. 26.
    1. Jiang  WJ, 
    2. Xu  XT, 
    3. Du  B, et al
    . Comparison of elective stenting of severe vs moderate intracranial atherosclerotic stenosis. Neurology 2007;68:420–26 doi:10.1212/01.wnl.0000252939.60764.8e pmid:17283316
  27. 27.
    1. Jiang  WJ, 
    2. Yu  W, 
    3. Du  B, et al
    . Outcome of patients with ≥70% symptomatic intracranial stenosis after Wingspan stenting. Stroke 2011;42:1971–75 doi:10.1161/STROKEAHA.110.595926 pmid:21636814
  28. 28.
    1. Kim  KS, 
    2. Hwang  DH, 
    3. Ko  YH, et al
    . Usefulness of stent implantation for treatment of intracranial atherosclerotic stenoses. Neurointervention 2012;7:27–33 doi:10.5469/neuroint.2012.7.1.27 pmid:22454782
  29. 29.
    1. Lee  KY, 
    2. Chen  DY, 
    3. Hsu  HL, et al
    . Undersized angioplasty and stenting of symptomatic intracranial tight stenosis with Enterprise: evaluation of clinical and vascular outcome. Interv Neuroradiol 2016;22:187–95 doi:10.1177/1591019915609165 pmid:26542728
  30. 30.
    1. Li  G, 
    2. Wang  N, 
    3. Li  X, et al
    . Balloon-mounted versus self-expanding stent outcomes in symptomatic middle cerebral artery stenosis combined with poor collaterals in China: a multicenter registry study. World Neurosurg 2019 Jan 16 [Epub ahead of Print] doi:10.1016/j.wneu.2018.12.189 pmid:30659967
  31. 31.
    1. Li  TX, 
    2. Gao  BL, 
    3. Cai  DY, et al
    . Wingspan stenting for severe symptomatic intracranial atherosclerotic stenosis in 433 patients treated at a single medical center. PLoS One 2015;10:e0139377 doi:10.1371/journal.pone.0139377 pmid:26422692
  32. 32.
    1. Li  Y, 
    2. Tang  L, 
    3. Qi  D, et al
    . Correlation between high perfusion syndrome and stent restenosis after stent implantation. Exp Ther Med 2016;12:3675–79 doi:10.3892/etm.2016.3813 pmid:28101162
  33. 33.
    1. Lylyk  P, 
    2. Vila  JF, 
    3. Miranda  C, et al
    . Endovascular reconstruction by means of stent placement in symptomatic intracranial atherosclerotic stenosis. Neurol Res 2005;27(Suppl 1):S84–88 doi:10.1179/016164105X35495 pmid:16197831
  34. 34.
    1. Maier  IL, 
    2. Karch  A, 
    3. Lipke  C, et al
    . Transluminal angioplasty and stenting versus conservative treatment in patients with symptomatic basilar artery stenosis: perspective for future clinical trials. Clin Neuroradiol 2018;28:33–38 doi:10.1007/s00062-016-0528-x pmid:27506672
  35. 35.
    1. Miao  ZR, 
    2. Feng  L, 
    3. Li  S, et al
    . Treatment of symptomatic middle cerebral artery stenosis with balloon-mounted stents: long-term follow-up at a single center. Neurosurgery 2009;64:79–84 doi:10.1227/01.NEU.0000335648.31874.37 pmid:19050657
  36. 36.
    1. Park  S, 
    2. Kim  JH, 
    3. Kwak  JK, et al
    . Intracranial stenting for severe symptomatic stenosis: self-expandable versus balloon-expandable stents. Interv Neuroradiol 2013;19:276–82 doi:10.1177/159101991301900303 pmid:24070075
  37. 37.
    1. Park  SC, 
    2. Cho  SH, 
    3. Kim  MK, et al
    . Long-term outcome of angioplasty using a Wingspan stent, post-stent balloon dilation and aggressive restenosis management for intracranial arterial stenosis. Clin Neuroradiol 2020;30:159–69 doi:10.1007/s00062-019-00793-1 pmid:31123775
  38. 38.
    1. Qureshi  AI, 
    2. Hussein  HM, 
    3. El-Gengaihy  A, et al
    . Concurrent comparison of outcomes of primary angioplasty and of stent placement in high-risk patients with symptomatic intracranial stenosis. Neurosurgery 2008;62:1053–60; discussion 60–62 doi:10.1227/01.neu.0000325867.06764.3a pmid:18580803
  39. 39.
    1. Salik  AE, 
    2. Selcuk  HH, 
    3. Zalov  H, et al
    . Medium-term results of undersized angioplasty and stenting for symptomatic high-grade intracranial atherosclerotic stenosis with Enterprise. Interv Neuroradiol 2019;25:484–90 doi:10.1177/1591019919832244 pmid:30991867
  40. 40.
    1. Samaniego  EA, 
    2. Tari-Capone  F, 
    3. Linfante  I, et al
    . Wingspan experience in the treatment of symptomatic intracranial atherosclerotic disease after antithrombotic failure. J Neurointerv Surg 2013;5:302–05 doi:10.1136/neurintsurg-2012-010321 pmid:22544819
  41. 41.
    1. Shin  YS, 
    2. Kim  BM, 
    3. Suh  SH, et al
    . Wingspan stenting for intracranial atherosclerotic stenosis: clinical outcomes and risk factors for in-stent restenosis. Neurosurgery 2013;72:596–604; discussion 604 doi:10.1227/NEU.0b013e3182846e09 pmid:23277374
  42. 42.
    1. Suh  DC, 
    2. Kim  JK, 
    3. Choi  JW, et al
    . Intracranial stenting of severe symptomatic intracranial stenosis: results of 100 consecutive patients. AJNR Am J Neuroradiol 2008;29:781–85 doi:10.3174/ajnr.A0922
  43. 43.
    1. Tang  CW, 
    2. Chang  FC, 
    3. Chern  CM, et al
    . Stenting versus medical treatment for severe symptomatic intracranial stenosis. AJNR Am J Neuroradiol 2011;32:911–16 doi:10.3174/ajnr.A2409 pmid:21393399
  44. 44.
    1. Wang  X, 
    2. Wang  Z, 
    3. Wang  C, et al
    . Application of the Enterprise stent in atherosclerotic intracranial arterial stenosis: a series of 60 cases. Turk Neurosurg 2016;26:69–76 doi:10.5137/1019-5149.JTN.13350-14.1 pmid:26768871
  45. 45.
    1. Wang  ZL, 
    2. Gao  BL, 
    3. Li  TX, et al
    . Symptomatic intracranial vertebral artery atherosclerotic stenosis (≥70%) with concurrent contralateral vertebral atherosclerotic diseases in 88 patients treated with the intracranial stenting. Eur J Radiol 2015;84:1801–04 doi:10.1016/j.ejrad.2015.05.033
  46. 46.
    1. Wang  ZL, 
    2. Gao  BL, 
    3. Li  TX, et al
    . Outcomes of middle cerebral artery angioplasty and stenting with Wingspan at a high-volume center. Neuroradiology 2016;58:161–69 doi:10.1007/s00234-015-1611-8
  47. 47.
    1. Wolfe  TJ, 
    2. Fitzsimmons  BF, 
    3. Hussain  SI, et al
    . Long term clinical and angiographic outcomes with the Wingspan stent for treatment of symptomatic 50-99% intracranial atherosclerosis: single center experience in 51 cases. J Neurointerv Surg 2009;1:40–43 doi:10.1136/jnis.2009.000331 pmid:21994104
  48. 48.
    1. Yu  J, 
    2. Wang  L, 
    3. Deng  JP, et al
    . Treatment of symptomatic intracranial atherosclerotic stenosis with a normal-sized Gateway TM balloon and Wingspan TM stent. J Int Med Res 2010;38:1968–74 doi:10.1177/147323001003800610 pmid:21227000
  49. 49.
    1. Yu  SC, 
    2. Leung  TW, 
    3. Lee  KT, et al
    . Angioplasty and stenting of atherosclerotic middle cerebral arteries with Wingspan: evaluation of clinical outcome, restenosis, and procedure outcome. AJNR Am J Neuroradiol 2011;32:753–58 doi:10.3174/ajnr.A2363 pmid:21436335
  50. 50.
    1. Yu  SC, 
    2. Leung  TW, 
    3. Lee  KT, et al
    . Angioplasty and stenting of intracranial atherosclerosis with the Wingspan system: 1-year clinical and radiological outcome in a single Asian center. J Neurointerv Surg 2014;6:96–102 doi:10.1136/neurintsurg-2012-010608 pmid:23512176
  51. 51.
    1. Yue  X, 
    2. Xi  G, 
    3. Lu  T, et al
    . Influence of residual stenosis on clinical outcome and restenosis after middle cerebral artery stenting. Cardiovasc Intervent Radiology 2011;34:744–50 doi:10.1007/s00270-010-9989-5 pmid:20927521
  52. 52.
    1. Zhang  L, 
    2. Huang  Q, 
    3. Zhang  Y, et al
    . A single-center study of Wingspan stents for symptomatic atherosclerotic stenosis of the middle cerebral artery. J Clin Neurosci 2013;20:362–66 doi:10.1016/j.jocn.2012.03.033 pmid:23228656
  53. 53.
    1. Zhang  Y, 
    2. Rajah  GB, 
    3. Liu  P, et al
    . Balloon-mounted versus self-expanding stents for symptomatic intracranial vertebrobasilar artery stenosis combined with poor collaterals. Neurol Res 2019;41:704–13 doi:10.1080/01616412.2019.1610837 pmid:31030623
  54. 54.
    1. Zhang  Y, 
    2. Sun  Y, 
    3. Li  X, et al
    . Early versus delayed stenting for intracranial atherosclerotic artery stenosis with ischemic stroke. J Neurointerv Surg 2020;12:274–78 doi:10.1136/neurintsurg-2019-015035 pmid:31285375
  55. 55.
    1. Zhou  Y, 
    2. Hua  Y, 
    3. Jia  L, et al
    . Evaluation of interventional therapy for patients with intracranial vertebral artery stenosis by transcranial color-coded sonography. Ultrasound Med Biol 2016;42:44–50 doi:10.1016/j.ultrasmedbio.2015.08.006 pmid:26410007
  56. 56.
    1. Zhu  SG, 
    2. Zhang  RL, 
    3. Liu  WH, et al
    . Predictive factors for in-stent restenosis after balloon-mounted stent placement for symptomatic intracranial atherosclerosis. Eur J Vasc Endovasc Surg 2010;40:499–506 doi:10.1016/j.ejvs.2010.05.007 pmid:20554461
  57. 57.
    1. Zi  W, 
    2. Gong  Z, 
    3. Shuai  J
    . Novel approaches in evaluating and predicting the potential benefit of middle cerebral artery angioplasty and stenting. J Neuroimaging 2015;25:620–25 doi:10.1111/jon.12176
  58. 58.
    1. Turk  AS, 
    2. Levy  EI, 
    3. Albuquerque  FC, et al
    . Influence of patient age and stenosis location on Wingspan in-stent restenosis. AJNR Am J Neuroradiol 2008;29:23–27 doi:10.3174/ajnr.A0869 pmid:7989366
  59. 59.
    1. Duan  G, 
    2. Feng  Z, 
    3. Zhang  L, et al
    . Solitaire stents for the treatment of complex symptomatic intracranial stenosis after antithrombotic failure: safety and efficacy evaluation. J Neurointerv Surg 2016;8:680–84 doi:10.1136/neurintsurg-2015-011734 pmid:26041096
  60. 60.
    1. Derdeyn  CP, 
    2. Fiorella  D, 
    3. Lynn  MJ, et al
    ; SAMMPRIS Investigators. Nonprocedural symptomatic infarction and in-stent restenosis after intracranial angioplasty and stenting in the SAMMPRIS Trial (Stenting and Aggressive Medical Management for the Prevention of Recurrent Stroke in Intracranial Stenosis). Stroke 2017;48:1501–06 doi:10.1161/STROKEAHA.116.014537 pmid:28455321
  61. 61.
    1. Alenghat  FJ
    . The prevalence of atherosclerosis in those with inflammatory connective tissue disease by race, age, and traditional risk factors. Sci Rep 2016;6:20303 doi:10.1038/srep20303 pmid:26842423
  62. 62.
    1. Yue  X, 
    2. Yin  Q, 
    3. Xi  G, et al
    . Comparison of BMSs with SES for symptomatic intracranial disease of the middle cerebral artery stenosis. Cardiovasc Intervent Radiol 2011;34:54–60 doi:10.1007/s00270-010-9885-z pmid:20458585
  63. 63.
    1. Gröschel  K, 
    2. Schnaudigel  S, 
    3. Pilgram  SM, et al
    . A systematic review on outcome after stenting for intracranial atherosclerosis. Stroke 2009;40:e340–47 doi:10.1161/STROKEAHA.108.532713 pmid:19182081
  • Received March 31, 2020.
  • Accepted after revision May 22, 2020.
  


  
  



  



    

  



  

                
    

      

  

    

  
      
  
  

    


Advertisement